DMAP1 and lung carcinoma: The predicted inactivating missense and frameshift mutations in breast cancer that motivated this study and the mutations later identified in lung cancer are all heterozygous and localized downstream of the DMAP1 binding domain [4] (Fig. 1a), suggesting that such a mechanism could be active also in patient tumours.